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ABSTRACT
Most biological processes depend on the co-ordinated formation of protein–protein interactions. Besides
their importance for virus replication, several interactions between virus proteins have been proposed as
attractive targets for antiviral drug discovery, as the exquisite speciﬁcity of such cognate interactions
affords the possibility of interfering with them in a highly speciﬁc and effective manner. There is a
considerable need for new drugs active against herpesviruses, since available agents, most of which
target the polymerisation activity of the virus DNA polymerase, are limited by pharmacokinetic issues,
toxicity and antiviral resistance. A potential novel target for anti-herpesvirus drugs is the interaction
between the two subunits of the virus DNA polymerase. This review focuses on recent developments
using peptides and small molecules to inhibit protein–protein interactions between herpesvirus DNA
polymerase subunits.
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INTRODUCTION
Eight herpesviruses are known to infect humans,
and several of these viruses are important human
pathogens [1]. These viruses cause a wide variety
of diseases. Herpes simplex virus types 1 and 2
(HSV-1 and HSV-2) cause herpes labialis and
genitalis, keratoconjunctivitis and encephalitis;
human cytomegalovirus (HCMV) is responsible
for a variety of severe diseases in immunocom-
promised patients, including pneumonia, gastro-
intestinal disease and retinitis in transplant
recipients and in AIDS patients, and is also a
major cause of congenital defects in newborn
children; varicella-zoster virus (VZV) is the caus-
ative agent of chicken pox following primary
infection, but can reoccur in adults as herpes
zoster (shingles); other members of the family
include Epstein-Barr virus (EBV) and human
herpesvirus 6, 7 and 8 (HHV-6, HHV-7 and
HHV-8). Herpesvirus infections are increasing
because of the growing number of immunocom-
promised individuals, i.e., transplant recipients
and AIDS patients.
Antiviral agents licensed currently for the
treatment of herpesvirus infections include acy-
clovir and derivatives, ganciclovir, foscarnet and
cidofovir, all of which inhibit herpesvirus DNA
polymerases [2]. Acyclovir, ganciclovir and cid-
ofovir are nucleoside analogues which function as
DNA chain terminators, whereas foscarnet inhib-
its virus DNA polymerase through binding to its
pyrophosphate binding site. However, some of
these antiviral agents, e.g., ganciclovir and fos-
carnet, can produce toxic side-effects. In addition,
the emergence of virus strains resistant to com-
monly used anti-herpesvirus drugs is a growing
problem, particularly in immunocompromised
patients [3]. Therefore, there is still a great
demand for the discovery of new, more effective
and speciﬁc anti-herpesvirus agents.
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A novel strategy to inhibit virus replication is
based on the disruption of virus protein–protein
complexes by peptides or peptidomimetic com-
pounds that mimic part of the interaction between
subunits [4]. Many enzymes act as oligomer
complexes, so inhibitors may act by preventing
the formation of the active holoenzyme. Indeed,
the ﬁrst example in the literature of successful
disruption of a protein–protein interaction
involved an enzyme, the HSV-1 ribonucleotide
reductase (RR). HSV-1 RR is a tetramer consisting
of two large R1 subunits and two small R2
subunits [5]. In 1986, two independent groups of
researchers reported that the synthetic nonapep-
tide YAGAVVNDL, corresponding to the C-ter-
minus of the small subunit R2, could inhibit
HSV-1 RR activity speciﬁcally by disrupting the
interaction between the subunits [6,7]. Moreover,
when the YAGAVVNDL peptide was linked to a
protein carrier, the B subunit of Escherichia coli
heat-labile enterotoxin, the resulting fusion pro-
tein inhibited virus replication and RR activity in
HSV-1-infected cells speciﬁcally [8], thereby pro-
viding direct evidence of the antiviral efﬁcacy of
the YAGAVVNDL peptide in a cellular system.
Thus, the YAGAVVNDL peptide became the ﬁrst
example of a new class of inhibitors that act by
dissociating the subunits of multimeric enzymes.
Following these pioneering studies, a number
of other peptides have been identiﬁed which
disrupt protein–protein interactions between the
subunits of other virus enzymes, e.g., the herpes-
virus DNA polymerases. Replicative DNA
polymerases generally function as multiprotein
complexes, including a catalytic subunit and one
or more accessory proteins that modify the
properties of the core polypeptide. Analogously,
it has been shown that a two-subunit DNA
polymerase is a common theme among members
of the Herpesviridae family, as the virus enzyme
is composed of a catalytic subunit and an acces-
sory protein, which is proposed to act as a
processivity factor (Fig. 1). The best studied her-
pesvirus DNA polymerase is the HSV-1 polym-
erase, which is a heterodimer composed of two
proteins, UL30 and UL42 [9]; in HSV-2, the
infected cell-speciﬁc peptide (ICSP) 34,35 has
been shown to be the counterpart of UL42 [10].
VZV polymerase interacts with a DNA-binding
protein (encoded by gene 16) which also shows
sequence similarity with UL42 [11]; in equine
herpesvirus-1, proteins homologous to UL30 and
UL42 are encoded by ORF30 and ORF18, respect-
ively [12]. The HCMV DNA polymerase also
consists of two proteins, UL54 and UL44 [13].
Other examples include the two subunits of
pseudorabies virus DNA polymerase [14], the
BALF5 ⁄BMRF1 complex of EBV [15], the catalytic
subunit (Pol6) and the accessory protein (p41) of
HHV-6 DNA polymerase [16,17], and the Pol8
and PF-8 subunits of HHV-8 DNA polymerase
[18].
During the past few years, research interest has
focused on the development of new anti-herpes-
virus inhibitors which act by disrupting the
interaction between the subunits of herpesvirus
DNA polymerases, i.e., HSV-1 and HCMV DNA
polymerase. Efforts have been aimed at charac-
terising protein–protein interactions between the
enzyme subunits, and at identifying peptides and
small molecules that mimic either face of the
subunit interaction, and which are therefore able
to disrupt the virus protein complexes.
Herpes simplex virus DNA polymerase
The HSV-1 DNA polymerase is a heterodimer
composed of a catalytic subunit, Pol or UL30, and
an accessory protein, UL42, which stimulates the
Fig. 1. Disruption of the herpesvirus DNA polymerase
complex. (a) The DNA polymerase of herpesviruses is
composed of a catalytic subunit, which possesses basal
activity, and an accessory protein. By interacting with the
catalytic subunit, the accessory protein stimulates the
processivity of the enzyme. In both the HSV-1 and
the HCMV DNA polymerase, the region of the catalytic
subunit responsible for binding to the accessory protein
has been localised to the C-terminal region (here repre-
sented as a rectangle). (b) Peptides corresponding to the
C-terminal region of the catalytic subunit or small mole-
cules mimicking the side-chain of residues crucial for
subunit interaction are capable of disrupting the DNA
polymerase complex, thus inhibiting the processivity of the
virus enzyme.
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processivity of the enzyme [19,20] without increas-
ing the rate of catalysis per primer-binding event
[21]. Mutations of UL30 and UL42 which disrupt
the interaction between the two enzyme subunits
speciﬁcallywere shown to inhibit virus replication,
thus supporting the essential role of the
UL30 ⁄UL42 association [22–26]. This has led to
growing interest in the potential of this association
as a novel antiviral drug target for rationally
designed compounds that, by mimicking the pro-
tein interface, would prevent heterodimerisation.
For this reason, the identiﬁcation of the UL30
and UL42 regions responsible for the physical
and functional interaction of these two proteins
has been the subject of detailed investigation. For
UL42, initial attempts were unsuccessful [27]. It
was then shown that the N-terminal two-thirds of
the 488-residue UL42 protein are sufﬁcient for
both binding to, and stimulation of, UL30 [23,28–
30]; indeed, the ﬁrst 338 residues are sufﬁcient for
HSV-1 replication [23,28]. On the other hand, the
amino-terminal 20 amino-acids were shown not
to be required for either binding or stimulation of
UL30 [23]. Finally, random peptide display stud-
ies, coupled with mutational and calorimetric
analyses, identiﬁed residue Q171 as important for
binding to UL30 [31]. This residue lies within the
so-called ‘connector loop’, a long loop which
connects the two topologically similar domains of
UL42. Indeed, the Q171A substitution in UL42
drastically reduced both binding to, and stimula-
tion of, long-chain DNA synthesis by UL30 [31]. A
co-crystal structure of UL42 bound to a UL30
C-terminal peptide then showed the presence of a
hydrogen-bonding network which connects Q171
to the side-chain of UL30 residue R1229 [32].
The region of UL30 responsible for the interac-
tion with UL42 was localised initially to the
C-terminal 227 amino-acids [33]. Subsequent
investigations to identify the essential regions
demonstrated that the extreme C-terminus of
UL30 is necessary and sufﬁcient for speciﬁc
interaction with UL42 [22,25,26]. It is noteworthy
that this region of UL30 is not highly conserved
among any other herpesvirus or cellular DNA
polymerase, and that it is not necessary for
catalytic activity, making it particularly attractive
as a starting point for the de-novo design of new
speciﬁc anti-HSV drugs. Attempts to disrupt the
interaction of UL30 with UL42 resulted in
the identiﬁcation of peptides corresponding to
the last 36, 27 and 18 residues of UL30 (Fig. 2),
which inhibit the ability in vitro of UL42 to
stimulate both the rate of DNA synthesis and
the synthesis of long DNA chains by UL30, with
IC50 values of 2–30 lM [34,35]. Moreover, an
oligopeptide corresponding to the 27 C-terminal
amino-acids of UL30 inhibits virus replication
with an EC50 of 11 lM when delivered into
HSV-1-infected cells via a protein carrier (the
B subunit of E. coli heat-labile enterotoxin) [36].
It was proposed that the antiviral activity of
this 27mer, designated as ‘Pol peptide’, occurred
through the speciﬁc intracellular dissociation of
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Fig. 2. Inhibitory peptides or small molecules directed against subunit interactions of herpesvirus DNA polymerases. n.d.,
not determined. References: a[35]; b[34,36]; c[40]; d[52].
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the complex between UL30 and UL42 [36]. In
addition, the structure of Pol peptide, both alone
[37] and bound to the protein carrier [38], was
elucidated and a nuclear localisation signal was
identiﬁed in the inhibitory peptide [39].
Taken together, these studies established proof-
of-principle for blocking the UL30 ⁄UL42 interac-
tion as an antiviral strategy. The results also
suggested that Pol peptide, or peptidomimetic
derivatives, merit consideration as lead com-
pounds for the development of novel anti-HSV
therapeutic agents. In addition, biophysical
studies of the UL30 ⁄UL42 binding interface
demonstrated that, although numerous hydro-
phobic interactions are observed in the co-crystal
structure of UL42 bound to a UL30 C-terminal
peptide [32], only a few speciﬁc hydrogen bonds
are crucial determinants of binding energy.
Indeed, single amino-acid changes, i.e., substitu-
tions at positions corresponding to UL30 residues
1228 and 1229, or at UL42 residue 171, can disrupt
the UL30 ⁄UL42 interaction [31]. These residues
are involved in hydrogen bonds crucial for the
UL30 ⁄UL42 interaction [32]. Combined, these
ﬁndings suggested that disruption of a very few
bonds would be sufﬁcient to disrupt the interac-
tion between the two proteins, and that small
molecules targeting the relevant side-chains could
interfere with UL30 ⁄UL42 binding. This sugges-
tion was supported by the identiﬁcation, from a
library of c.16 000 small molecules, of a com-
pound, termed BP5 (Fig. 2), which inhibits the
physical interaction between UL30 and UL42, and
thus virus replication, speciﬁcally at concentra-
tions (0.3–2 lM) below those that cause cytotoxic
effects (20 lM) [40].
Human cytomegalovirus DNA polymerase
HCMV DNA replication has not been as well-
characterised as that of HSV; however, HCMV
homologues of six of the seven proteins essential
for HSV-1 replication [41] have been identiﬁed
[42]. These homologues include the two subunits
of the DNA polymerase, which is composed of a
1242-residue catalytic subunit, Pol or UL54
[43,44], and a 433-residue accessory protein,
UL44 or infected-cell protein 36 (ICP36) [13].
The HCMV DNA polymerase has a number of
characteristics in common with its HSV-1 coun-
terpart. The UL54 protein, which is the homo-
logue of HSV-1 UL30, possesses DNA-dependent
DNA polymerase activity [45] as well as 3¢-5¢
exonuclease activity [46]. Both these activities are
dependent on the salt concentration [47], in a
manner very similar to that observed for the HSV-
1 DNA polymerase [48]. The HCMV UL44 acces-
sory subunit is analogous to the HSV-1 UL42
protein. Like UL42, UL44 has been shown to bind
double-stranded DNA with high afﬁnity, to spe-
ciﬁcally interact with UL54, and to stimulate long-
chain DNA synthesis, possibly by increasing the
processivity of the polymerase along the DNA
template [13,49]. Although the HCMV accessory
protein has little sequence homology to UL42 and
to the accessory proteins of other herpesviruses, it
has been predicted that it possesses a similar
‘processivity fold’ structure [32].
The observations that both UL54 and UL44 are
essential for HCMV DNA replication [42,50], that
inhibition of UL44 synthesis in HCMV-infected
cells inhibits virus DNA replication strongly [51],
and that the UL54 ⁄UL44 interaction is speciﬁc
[52], suggested that such an interaction might be
an attractive target for antiviral drugs. However,
in contrast to the relatively detailed understand-
ing of the HSV-1 UL30 ⁄UL42 interaction, the
interaction between the two subunits of HCMV
DNA polymerase, UL54 and UL44, has taken
longer to elucidate.
To characterise the HCMV DNA polymerase,
the two subunits, UL54 and UL44, have been
expressed and puriﬁed from insect cells infected
with recombinant baculoviruses [52]. In order to
localise the UL44-binding site on UL54, overlap-
ping peptides spanning the C-terminal region of
UL54 were synthesised and tested for inhibition
of the UL54 ⁄UL44 interaction by two independent
methods [52].
First, by means of an interaction ELISA, it was
found that a peptide corresponding to the
C-terminal 22 amino-acids of UL54 (residues
1221–1242) blocked the physical interaction
between Ul54 and UL44. The concentration of
peptide required to obtain 50% inhibition was
c.11 lM (Fig. 2), a value comparable with that
observed (2–30 lM) for inhibition of the HSV-1
UL30 ⁄UL42 interaction by UL30 C-terminal pep-
tides [34,35]. Interestingly, the UL54 C-terminus
presents two carboxy-terminal cysteines, which
are uncommon among herpesvirus DNA polym-
erases and are important for the inhibitory activ-
ity of the peptide. Removal of one cysteine from
the extreme C-terminus of the inhibitory peptide
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diminished the capability of the peptide to inter-
fere with the physical interaction between UL54
and UL44, while deletion of the two cysteines
impaired the inhibitory activity of the peptide
substantially [52]. These results suggested that
these residues of UL54 might be involved in the
interaction with UL44, either by binding UL44
directly, or by stabilising a structure within UL54
itself that can bind subsequently to UL44.
Second, the ability of the peptides spanning the
UL54 C-terminal region to inhibit enzyme activity
in vitro was analysed. The results demonstrated
that the C-terminal 22mer inhibits the UL54 ⁄UL44
functional interaction efﬁciently. The concentra-
tion of C-terminal peptide required to inhibit
UL54 ⁄UL44 activity by 50% was very similar to
the IC50 for inhibition of the physical interaction
(20 lM vs. 11 lM) (Fig. 2). Inhibition of the
HCMV UL54 ⁄UL44 activity by the UL54 C-ter-
minal peptide appeared to be speciﬁc, since the
peptide did not inhibit the HSV-1 UL30 ⁄UL42
interaction at a concentration as high as 1 mM,
and a peptide corresponding to the 27 C-terminal
residues of HSV-1 UL30 (aa 1209–1235) did not
inhibit the HCMV UL54 ⁄UL44 interaction [52].
Importantly, these ﬁndings demonstrated that
successful, speciﬁc inhibition of HCMV DNA
polymerase can indeed be obtained through
disruption of the interaction between the two
enzyme subunits.
In addition, these data suggested that the
extreme C-terminus of UL54 might be involved
in the interaction with UL44. To address this
hypothesis, the binding to UL44 of peptides cor-
responding to the extreme C-terminus of UL54
was measured quantitatively using isothermal
titration calorimetry (ITC). A peptide correspond-
ing to the last 22 residues of UL54 was sufﬁcient
to bind speciﬁcally to UL44 in a 1 : 1 complex
with a dissociation constant of c.0.7 lM [53].
Moreover, the deletion of this segment from
UL54 prevented binding to UL44 [53]. These
results demonstrated that this relatively small
region of UL54 is both necessary and sufﬁcient for
UL44 binding. Conversely, a shorter peptide,
corresponding to the last 10 residues, exhibited
no detectable binding to UL44 in solution, and no
detectable inhibitory activity against DNA syn-
thesis by UL54 and UL44. Thus, this shorter
region of UL54 is not sufﬁcient for the interaction
with UL44. However, although the C-terminal 10-
residue segment is not sufﬁcient for UL44 bind-
ing, the extreme C-terminus of UL54 is involved
in the UL54 ⁄UL44 interaction, as deletion of the
two C-terminal cysteines reduced binding of the
UL54 C-terminal peptide and of full-length UL54
to UL44 [53].
These ﬁndings demonstrated clearly that the
extreme C-terminus of HCMV UL54 is crucial for
binding UL44, as is the C-terminus of HSV-1
UL30 for its interaction with UL42. Remarkably,
despite this functional analogy of the C-terminus
of UL54 to that of UL30, there is almost no
sequence homology, and in fact, neither the HSV-
1 nor the HCMV catalytic subunits are stimulated
by the non-cognate accessory protein. In addition,
other features of the interaction between UL54
and UL44 that are reminiscent of the interaction
between UL30 and UL42 have been highlighted.
First, the C-terminal region of UL54 can fold into
a helical structure, as already reported for the
C-terminus of HSV-1 UL30 [32,54]. In fact, circular
dichroism (CD) spectroscopy of the UL54
C-terminal peptide in 2,2,2-triﬂuoroethanol
(TFE) ⁄water indicated that this peptide has some
propensity to adopt a partially a-helical structure
[52]. The helicity of the peptide was apparently
independent of peptide concentration, thereby
suggesting that it is monomeric, as was found for
the C-terminal UL30 peptides [35]. Second, a
nuclear localisation signal, RRLHL, was identiﬁed
within the C-terminal region of HCMV UL54, and
a functionally equivalent sequence, correspond-
ing to residues RRMLHR, was found also in the
C-terminus of HSV-1 UL30 [39]. Third, like HSV-1
UL42, HCMV UL44 is a DNA-binding protein
[55] that is essential for virus replication [42,50],
associates speciﬁcally with the catalytic subunit,
and stimulates long-chain DNA synthesis [13,49].
The UL54- and DNA-binding activities of UL44
reside within the N-terminal two-thirds; as for
UL42, the C-terminus is dispensable [49].
To further characterise the UL54 ⁄UL44 interac-
tion, individual residues in UL54 that are crucial
for binding to UL44 were deﬁned. For this
purpose, a series of mutations was engineered
in the C-terminal region of UL54, and the effect of
the mutations was tested on physical and func-
tional interaction between UL54 and UL44 [53].
Initial studies focused on the last two residues of
UL54, as previous studies had shown that a
mutant UL54 C-terminal peptide lacking the two
carboxy-terminal cysteines was >40-fold less
potent than the wild-type peptide for disruption
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of the physical interaction between UL54 and
UL44, suggesting an important role for these
residues in the UL54 ⁄UL44 interaction [52]. The
results of mutational analysis demonstrated that
the two C-terminal cysteines of UL54 probably
play a role in the UL54 ⁄UL44 interaction, but not
an essential one. In fact, a mutant UL54 peptide
lacking the two C-terminal cysteines still bound
UL44 in solution, although with an afﬁnity lower
than that of the wild-type peptide [53]. Consistent
with these data, the deletion of these two residues
in full-length UL54 caused only a partial impair-
ment in the ability of UL54 to interact with UL44
in glutathione S-transferase (GST)-pulldown
assays. Moreover, substitution of either or both
the C-terminal cysteines with alanine did not
cause any signiﬁcant effect on binding of UL54 to
UL44. These ﬁndings suggested that interactions
between UL44 and the extreme C-terminus of
UL54 probably involve the main chain of the two
C-terminal cysteines rather than their side-chains.
Similarly, the crystal structure of the HSV-1
UL42 ⁄UL30 peptide complex revealed that the
last two residues of the UL30 peptide, Leu1234
and Ala1235, interact with UL42 via hydrogen
bonds between the main chain carbonyl oxygens
and the amino-group of the Lys289 side-chain of
UL42 [32].
Next, ‘alanine scan’ mutants of UL54, in which
each non-alanine residue in the region correspond-
ing to the last 22 residues of UL54 was individu-
ally converted to an alanine, were created and
tested for their ability to bind UL44 [53]. Substi-
tution of Leu1227 or Phe1231 in UL54 impaired
greatly both the UL54 ⁄UL44 interaction in pull-
down assays and long-chain DNA synthesis, but
without affecting basal polymerase activity, there-
by identifying these residues as important for
subunit interaction [53]. Thus, these observations
highlight both similarities and differences
between the UL54 ⁄UL44 and UL30 ⁄UL42 inter-
actions. Both in HSV-1 and in HCMV DNA poly-
merase, a few residues are crucial for the binding
of the catalytic subunit with the cognate accessory
protein. However, the side-chains of the residues
that have been identiﬁed as important for HSV-1
UL30 ⁄UL42 and for HCMV UL54 ⁄UL44 interac-
tion are remarkably different, being basic in the
ﬁrst case and hydrophobic in the latter. In fact,
although two basic residues of UL54, Arg1224
and His1226, also seem to participate in UL44
binding, they are not crucial [53]. As both the
Leu1227-to-Ala and the Phe1231-to-Ala change
substituted a larger side-chain for a smaller one,
while maintaining the hydrophobic character of
the residue, it can be speculated that large side-
chains at these positions in UL54 are necessary to
make intermolecular contacts with UL44. The
importance of an aromatic hydrophobic side-
chain at position 1231 of UL54 for UL44 binding
is suggested by the observation that substitution
of Phe1231 with a tyrosine restores both binding
to UL44 in pulldown assays and long-chain DNA
synthesis by UL54 in the presence of UL44 [53].
The crystal structure of residues 1–290 of UL44
has been elucidated to a resolution of 1.85 A˚ by
multiwavelength anomalous dispersion [56]. The
crystal structure of UL44 revealed an overall fold
that was strikingly similar to that of UL42, despite
the fact that the HCMV accessory protein has very
little sequence homology to UL42. Moreover, as
well as UL42, UL44 possesses a ‘connector loop’, a
structural element that connects two topologically
similar domains of the protein [32]. In UL42, the
connector loop has been shown to be crucial for
interaction with its cognate catalytic subunit,
UL30 [31].
To investigate whether the UL44 connector
loop might be involved in the interaction with
UL54, each of its amino-acids (aa 129–140) was
substituted with alanine [57]. The effect of each
substitution on the UL44 ⁄UL54 interaction was
then tested using GST-pulldown and ITC assays,
as well as the effect on the stimulation of UL54-
mediated long-chain DNA synthesis by UL44,
and on the binding of UL44 to DNA-cellulose
columns. Substitutions that affect residues
133–136 of the connector loop impaired the
UL44 ⁄UL54 interaction measurably, but without
altering the ability of UL44 to bind DNA. One
substitution, I135A, disrupted the binding of
UL44 to UL54 completely and also inhibited the
ability of UL44 to stimulate long-chain DNA
synthesis by UL54. Thus, similar to the
UL30 ⁄UL42 interaction, a residue of the connector
loop of the accessory subunit is crucial for
UL54 ⁄UL44 interaction. However, although resi-
due(s) of both UL44 and of UL42 that are
important for binding to the cognate catalytic
subunit reside in the connector loop, it remains to
be determined whether the role played by these
residues is similar or different in the two systems.
Two observations hint at differences. First,
weak binding of UL30 could be detected with
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the UL42 Q171A mutant in maltose binding pro-
tein (MBP)-pulldown assays, and a small release
of heat was measured by ITC when a large excess
of an UL30 C-terminal peptide was added to the
Q171A mutant [31]. In contrast, the I135A substi-
tution of UL44 impaired binding to UL54 in
GST-pulldown assays completely and also
reduced the afﬁnity forUL54C-terminal peptide to
unquantiﬁable levels in ITC experiments. Second,
Q171 is a polar residue while I135 is nonpolar.
Thus, although the residues most important for
DNA polymerase subunit interactions lie in anal-
ogous regions, i.e., the C-terminus of the catalytic
subunit and the connector loop of the accessory
protein, the molecular details of the HCMV
UL54 ⁄UL44 interaction are likely to be different
from those of the interaction between its HSV
counterparts. In particular, the UL44 ⁄UL54 inter-
action is likely to be more dependent upon
hydrophobic interactions, since two of the resi-
dues of the UL44 connector loop that are most
important for binding to UL54 (I135 and V136) are
hydrophobic. Similarly, UL54 residues important
for UL44 binding are hydrophobic [53], whereas
those of UL30 which are important for interaction
with UL42 are basic [31,32]. Consistent with this
idea are the DH values, which are higher for the
HCMV interaction than for the HSV-1 interaction
[31,53], and may relate to the more crucial role of
hydrophobic vs. hydrophilic residues in the two
systems. This contrasts with the UL30 ⁄UL42
interaction, where a few speciﬁc hydrogen bonds
between polar residues comprise the crucial
sequence-speciﬁc determinants for binding
[31,32].
The differences between the HCMV and HSV
DNA polymerase subunit interactions probably
account for the fact that these interactions are
speciﬁc, since non-cognate partners do not bind
[52]. As the residues most important for HSV-1
UL30 ⁄UL42 and for HCMV UL54 ⁄UL44 interac-
tion are not conserved, small molecule inhibitors
that target the residue side-chains could be
signiﬁcantly more virus-speciﬁc than most of the
drugs currently licensed for antiherpesvirus che-
motherapy. In support of this hypothesis, some
small molecules able to block the UL54 ⁄UL44
interaction speciﬁcally in vitro, as well as HCMV
replication, have been identiﬁed (A. Loregian and
D. M. Coen, unpublished results).
Another potentially interesting antiviral target
could be the UL44 protein itself. Indeed, the
crystal structure revealed that, despite the fact
that UL44 has an overall fold strikingly similar to
that of HSV-1 UL42, UL44 can form a C-clamp-
shaped dimer [56], whereas UL42 is a monomer
both in solution and in the crystal structure
[32,58]. These ﬁndings suggest that HSV and
HCMV processivity factors adopt different oligo-
meric states during virus DNA replication. UL44
dimerises across one of the crystallographic two-
fold axes, and the interaction between the two
monomers entails an antiparallel b interaction,
which involves six main-chain-to-main-chain
hydrogen bonds and extensive packing of hydro-
phobic side-chains at the interface. F121 of each
monomer is buried against a hydrophobic loop
composed of P85, L86 and L87 of the other
monomer. L86 and L87 also pack against M123
and L93 of the opposite monomer. These interac-
tions entail a fairly large interface (c.1100 A˚). Both
the nature and the extent of the interactions
suggest that the dimerisation is likely to be
biologically relevant and not an artefact of crys-
tallographic packing. Indeed, analytical ultracen-
trifugation and gel ﬁltration measurements
demonstrated that UL44 also forms a dimer in
solution [56]. Sedimentation equilibrium analysis
was also employed todetermine adissociation con-
stant for UL44 dimerisation of 243 ± 63 nM [56].
To conﬁrm that the residues identiﬁed in the
dimer interface of the UL44 crystal structure are
indeed crucial for UL44 homodimerisation, three
mutant constructs, F121A, L86A ⁄L87A and P85G,
were created [56]. The F121A and L86A ⁄L87A
mutations were predicted to affect UL44 dimeri-
sation, as these residues make extensive contacts
with hydrophobic residues along the dimer
interface. In contrast, the P85G substitution was
expected to have a minor or no effect, as the P85
residue is not buried so signiﬁcantly at the dimer
interface. Indeed, gel ﬁltration experiments dem-
onstrated that the P85G mutant behaves as a
dimer in a similar way to the wild-type protein,
while the F121A and L86A ⁄L87A mutants behave
as monomers.
Finally, in order to determine whether dimeri-
sation of UL44 affects DNA binding, the ability of
the UL44 mutants that are altered at the dimer
interface to bind DNA was investigated [56]. The
mutant P85G, which could dimerise, displayed an
afﬁnity for DNA similar to that of the wild-type
protein. In contrast, the F121A and L86A ⁄L87A
mutants, which behaved as monomers in gel
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ﬁltration experiments, had afﬁnities for DNA that
were 10- to 100-fold lower than that of the wild-
type protein. These data suggest that the dimeri-
sation of UL44 could play an important role in its
activity as a DNA polymerase processivity factor,
and therefore that the UL44 homodimeric inter-
face may be exploited in the design of novel
antiviral agents.
CONCLUSIONS
The importance and speciﬁcity of protein associ-
ations in virus replication and pathogenesis make
protein–protein interactions attractive targets for
therapeutic intervention. Compounds capable of
interfering selectively with such interactions
represent novel potential agents for antiviral
therapy. However, although the disruption of
speciﬁc protein–protein contacts is a promising
strategy for drug development, the nature of these
interactions can make this goal impractical. Many
protein–protein interactions involve large surfa-
ces or multiple contacts, making it unlikely that a
single small molecule could interfere with them.
Recent studies on herpesvirus DNA polym-
erases, i.e., those of HSV-1 and HCMV, have
identiﬁed important aspects of the subunit inter-
face. In both the HSV-1 UL30 ⁄UL42 and HCMV
UL54 ⁄UL44 interactions, only a relatively small
surface appears to be necessary and sufﬁcient for
binding between the catalytic subunit and the
cognate accessory protein; indeed, the substitu-
tion of single residue side-chains is sufﬁcient to
disrupt the subunit interaction and to inhibit the
activity of the holoenzyme. These ﬁndings herald
the prospect that inhibitors targeting the residue
side-chains could interfere with the HSV-1-
UL30 ⁄UL42 or HCMV UL54 ⁄UL44 interactions.
Moreover, as the side-chains of the residues that
are crucial for UL30 ⁄UL42 and UL54 ⁄UL44
interaction are remarkably different, such inhib-
itors could be signiﬁcantly more virus-speciﬁc
than most of the drugs currently licensed
for antiherpesvirus chemotherapy, and would
therefore represent novel, attractive antiviral
compounds.
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